GBM has been targeted with many inhibitors of angiogenesis including tissue inhibitors of matrix metalloproteinases[11-13], chemokines [14-16], tyrosine kinase inhibitors [17-20], interleukins [21,22], and naturally occurring proteolytic fragments of large precursor molecules such as endostatin, vasostatin, canstatin, angiostatin and others [23-29]. Here, COL18A1 is linked to glioblastoma.